APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
Author :
Richa Dwivedi†, Youya Wang†, Christopher Kline, Douglas K. Fischer, Zandrea Ambrose*Volume:
2 issue:Year:2022 Views : 261
APA:Richa Dwivedi†, Youya Wang†, Christopher Kline, Douglas K. Fischer, Zandrea Ambrose*. (Volume-2, Issue- -(Year-2022)). APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants. Retrieved from https://pubmed.ncbi.nlm.nih.gov/35957953/
Chicago:Richa Dwivedi†, Youya Wang†, Christopher Kline, Douglas K. Fischer, Zandrea Ambrose*. "APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants" Example, Volume-2-issue--Year-2022-1664302X. https://pubmed.ncbi.nlm.nih.gov/35957953/.
